Hangzhou (1)

Hepatocellular Carcinoma (1)

Lenvatinib (1)

Oxaliplatin (1)

Pharmorubicin (1)

TACE (1)

Tislelizumab (1)

Not yet recruiting (1)

phase 2 (1)

Zhejiang Cancer Hospital (1)

tace (1)

tislelizumab, lenvatinib (1)

drug (1)

procedure (1)

Other (1)

Interventional (1)

pharmorubicin

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Not yet recruiting

Jun 17, 2023